Innovation funding: the complete map of RDI incentives for 2026
CDTI alone will mobilise more than €1.8 billion in 2026 to support business innovation in Spain (source: CDTI, cdti.es). And yet a significant share of the tech companies investing in R&D and innovation fail to recover everything the law allows them: they leave tax deductions on the table, do not apply for grants they are eligible for, or are simply unaware of the social security rebates available for their research staff. Innovation funding is not a single instrument — it is a portfolio of levers that work best in combination. This article is the complete map for your organisation to activate all of them.
If your company develops software, deploys artificial intelligence, improves production processes or launches new products, you are almost certainly generating activity that qualifies for one or more of these mechanisms. The difference between an innovation project that partially funds itself and one paid for entirely out of your own cash is rarely about the technology — it is about the financial strategy that accompanies it.
Key insight: innovation funding is built by stacking compatible incentives — tax deductions + grants + social security rebates — and, when organic growth is not enough, adding M&A as an inorganic lever. Organisations that design the combination from the very start of a project multiply their return.
What is innovation funding and what levers does it comprise?
Innovation funding is the set of public and private instruments that allow a company to reduce the net cost of its R&D and innovation activities (research, development and technological innovation) and accelerate its growth. In Spain, for a tech company, it revolves around four main levers that are worth understanding — and, above all, combining:
- R&D tax deductions (Article 35 of the Spanish Corporate Income Tax Law, Ley 27/2014): a fiscal incentive that reduces the corporate tax liability in proportion to innovation expenditure.
- Public grants and subsidies (CDTI, Misiones, Neotec, Cervera, Innterconecta-STEP, Innoglobal): non-repayable funding or soft loans for specific projects.
- Social security rebates for research staff (Royal Decree 475/2014): a reduction in employer contributions for ordinary contingencies.
- M&A (mergers and acquisitions) as an inorganic growth lever: acquiring capabilities, technology or market share that would be slow or expensive to build in-house.
Each lever has its own rules, deadlines and requirements. The important point is that they are not mutually exclusive: the tax deduction and the social security rebate are compatible under certain conditions, and both coexist with grants. Below we walk through each at a high level and point you to the cluster's dedicated analyses for the operational detail.
R&D tax deductions: the most powerful and least-used incentive
The tax deduction under Article 35 of the Corporate Income Tax Law is, for most tech companies, the highest-impact incentive and, paradoxically, one of the most under-used. It works by directly reducing the corporate tax liability in proportion to R&D and innovation expenditure, and it distinguishes two categories of activity with very different rates.
| Category | Deduction rate | Base |
|---|---|---|
| R&D — base deduction | 25% | R&D expenditure for the year |
| R&D — on the excess | 42% | Excess over the average of the previous 2 financial years |
| R&D — research staff | +17% additional | Expenditure on qualified research staff exclusively assigned to R&D |
| R&D — related investments | +8% additional | Tangible/intangible fixed assets (excluding buildings and land) used for R&D |
| Technological Innovation (TI) | 12% | Technological innovation expenditure for the year |
Correct project classification is decisive: what qualifies as R&D can attract a deduction of up to 42% on incremental expenditure, while technological innovation is capped at 12%. This is why properly documenting and categorising each activity is essential. In the case of software development — where the boundary between R&D and TI is particularly delicate — we recommend the detailed analysis in the R&D tax deduction applied to software development.
What if my company does not have enough tax liability to apply the deduction?
Short answer: monetisation exists. Article 39.2 of the Corporate Income Tax Law allows the R&D deduction to be applied without any liability cap — and even claimed as a cash payment from the tax authority when there is no tax to pay — in exchange for a 20% discount on the deductible amount, provided certain requirements are met (maintaining headcount, reinvesting the amount in R&D and innovation, and obtaining a binding report). This is especially valuable for start-ups and companies in intensive investment phases that have not yet reached profitability but are incurring eligible expenditure. Monetisation turns a "dormant" tax credit into real liquidity.
Key takeaway: if your company invests in R&D but is loss-making or has a low tax liability, do not give up on the deduction. Monetisation under Article 39.2 of the Corporate Income Tax Law lets you collect it with a 20% discount. That is the difference between a theoretical incentive and cash in the bank.
Grants and innovation subsidies: the CDTI ecosystem in 2026
Grants are the second major lever and, in 2026, the context is favourable: CDTI will mobilise more than €1.8 billion to drive business innovation (source: CDTI). CDTI structures its support through several programmes, each aimed at a different company and project profile.
| CDTI Programme | Focus | Key 2026 data |
|---|---|---|
| Neotec | Young technology-based companies | Grant of up to 70% of eligible budget, maximum €250,000 per beneficiary; applications open 14 April to 14 May 2026 |
| Misiones Ciencia e Innovación | Collaborative projects, national challenges | €60M budget; maximum intensity 65% large company, 75% medium, 80% small |
| Cervera | Priority technologies | R&D financing line |
| Innterconecta-STEP | Regional collaborative projects | Co-financing of collaborative R&D |
| Innoglobal | International technological cooperation | International projects |
Unlike the tax deduction — which is automatic when requirements are met — grants are competitive, have fixed deadlines (Neotec 2026 windows open from 14 April to 14 May), and require a high-quality technical and financial proposal. Preparing a strong application takes weeks, so planning ahead is critical. For detail on each programme, eligibility requirements and proposal preparation tips, see our guide to R&D grants for tech companies.
A strategic point: grants and the tax deduction are compatible, but the subsidised amount reduces the deduction base — you cannot deduct the same euro twice. This is precisely where joint planning of both instruments — deciding which expenditure is covered by the grant and which is reserved for the deduction — is where good advisory adds the most value.
Social security rebates for research staff
The third lever tends to go unnoticed and yet has a direct impact on the labour cost of the R&D team. Royal Decree 475/2014 establishes a 40% rebate on employer social security contributions for ordinary contingencies applicable to research staff exclusively dedicated to R&D and innovation activities.
Is it compatible with the tax deduction? Yes, under the terms of Royal Decree 475/2014 itself:
- SMEs holding the "Innovative SME" seal or technology-based companies (EBT) can combine the rebate and the deduction directly.
- Other companies can do so by providing a binding report certifying the activity.
This rebate reduces the real cost of maintaining a research team, making it a natural complement to the tax deduction: the deduction rewards R&D expenditure, and the rebate specifically reduces the payroll cost of those who carry it out. The combination of both is one of the highest-return decisions available — and one of the most commonly overlooked. We go deeper into the exclusivity requirements, the Innovative SME seal and compatibility in the article on social security rebates for research staff.
The Binding Motivated Report: legal certainty for your deduction
Claiming an R&D tax deduction or combining the rebate with the deduction carries a risk: that Spain's Tax Agency (Agencia Tributaria), during an inspection, reclassifies the project or challenges its nature. The tool that neutralises this risk is the Binding Motivated Report (Informe Motivado Vinculante, IMV).
The IMV is issued by a certification body accredited by ENAC, and its effect is decisive: the motivated report is binding on the Tax Agency with regard to the fiscal classification of the project. In other words, it shields the deduction against any potential review, providing legal certainty for the incentive. For projects of a certain size — and especially for artificial intelligence projects, where the line between R&D and technological innovation demands rigorous technical argumentation — the IMV is not an optional formality but an investment in certainty. We develop this in the specific case of an AI project in the Binding Report for an R&D and innovation project in artificial intelligence.
M&A as a growth lever: when innovating means acquiring
Not all innovation is built in-house. When time to market is critical, when a specific technological capability would be slow or expensive to build internally, or when critical mass is needed to compete, inorganic growth via M&A (mergers and acquisitions) becomes a first-order strategic lever. Acquiring a company with the technology, talent or market share your organisation needs can be more efficient than developing them from scratch.
A well-executed M&A transaction covers the full cycle:
- Valuation of the target asset or company.
- Due diligence (financial, legal, technological) to understand what is actually being acquired.
- Buyer or seller search depending on which side of the deal you are on.
- Negotiation of terms and structure.
- Post-acquisition integration, the phase where the deal's value is won or lost.
M&A does not replace the tax and grant levers — it complements them. A company can grow organically by leveraging deductions and subsidies, and make an inorganic leap through a strategic acquisition. The key is that both strategies serve the same innovation plan. If you want to understand when and how M&A accelerates the growth of a tech company, read our analysis on M&A and mergers and acquisitions of technology companies.
How to combine the levers: a financial strategy for innovation
The most common mistake is treating each incentive in isolation and reactively: claiming the deduction at year-end, discovering a grant call too late, ignoring the social security rebate, and considering M&A only when a buyer is already knocking at the door. The winning strategy is the opposite: design the innovation funding structure at the start of the project and stack incentives deliberately.
A high-level decision framework:
- Classify the activity: is it R&D (up to 42%) or technological innovation (12%)? The correct classification changes the return.
- Identify the right grant and its timeline (Neotec, Misiones, Cervera…), allowing time to prepare the proposal.
- Activate the social security rebate for exclusively dedicated research staff.
- Secure the incentive with a Binding Motivated Report if the project warrants it.
- Plan monetisation (Article 39.2 of the Corporate Income Tax Law) if the tax liability is insufficient.
- Assess M&A as an inorganic growth route when internal development cannot meet the timeline.
This is where expert guidance makes the difference. At Technova we collaborate with Tecnocim Innova to design and implement this end-to-end innovation financial strategy. With more than 30 years of experience, their team covers strategic consulting, R&D grants, R&D tax deductions — where they help recover up to 42% of the innovation investment — social security rebates (up to 40%), and full M&A and industrial transfer transactions. Their track record is backed by European Union funds, the Spanish Ministry of Industry and Tourism, and EOI (Escuela de Organización Industrial), under a tagline that sums up their approach well: "Strategy with impact, innovation with value." This is not marketing — it is leadership supported by verifiable credentials.
From the technology side, Technova brings the other half of the equation: the innovation that is subsequently funded. Our Data and Artificial Intelligence services and AI training for teams generate precisely the R&D and innovation activity that these incentives are designed to reward.
Frequently Asked Questions
What is innovation funding?
It is the set of public and private instruments that reduce the net cost of a company's R&D and innovation activities and accelerate its growth. In Spain it includes tax deductions (Article 35 of the Corporate Income Tax Law), grants (CDTI, Neotec, Misiones), social security rebates for research staff (Royal Decree 475/2014) and, as an inorganic growth lever, M&A transactions. The defining characteristic is that these instruments are designed to be combined.
Are tax deductions compatible with grants?
Yes. The R&D deduction under Article 35 of the Corporate Income Tax Law and grants are compatible, but the subsidised amount reduces the deduction base — you cannot deduct the same euro of expenditure twice. It is therefore advisable to plan jointly which part of the project is covered by the grant and which part is reserved for the deduction.
What percentage can I deduct for R&D?
The base R&D deduction rate is 25% of the year's expenditure, rising to 42% on the excess over the average of the previous two financial years. An additional 17% applies to expenditure on qualified research staff exclusively assigned to R&D, and an additional 8% applies to investments in related fixed assets. Technological innovation attracts a 12% deduction.
Can I claim the deduction if my company is not profitable?
Yes, through monetisation under Article 39.2 of the Corporate Income Tax Law. This allows the deduction to be applied without any liability cap, and even claimed as a cash payment from the tax authority, with a 20% discount on the amount, provided the requirements for maintaining headcount, reinvesting in R&D and innovation, and obtaining a binding report are met. It is particularly useful for start-ups and companies in an investment phase.
What is the Binding Motivated Report and why does it matter?
It is a report issued by a certification body accredited by ENAC that classifies the project as R&D or technological innovation. Its value lies in the fact that it is binding on Spain's Tax Agency, providing legal certainty and shielding the deduction against a potential inspection. It is highly advisable for projects of a certain scale or of technically complex nature, such as those involving artificial intelligence.
When does M&A make more sense than developing innovation in-house?
M&A is preferable to internal development when time to market is critical, when the required technological capability would be very slow or expensive to build, or when critical mass is needed to compete. It does not replace the tax and grant levers; it complements them within the same growth plan.
Conclusion
Innovation funding is not a year-end administrative task — it is a strategy designed at the start of each project that stacks compatible incentives: tax deductions of up to 42%, grants from a CDTI that will mobilise more than €1.8 billion in 2026, social security rebates of up to 40%, and, where appropriate, M&A as an inorganic accelerator. Companies that approach this in an integrated way recover a substantial portion of their R&D and innovation investment; those that tackle it in a fragmented way leave money on the table.
Your next step: do not let tax and funding complexity hold back your innovation. Tell us about your project and we will help you design the technology and financial strategy to make it viable.
Talk to a Technova expert and let us build together the plan that turns your innovation investment into a funded competitive advantage.
Sources: Spanish Tax Agency (Agencia Tributaria); Law 27/2014, of 27 November, on Corporate Income Tax (Articles 35 and 39.2); CDTI (cdti.es); Royal Decree 475/2014, of 13 June, on social security contribution rebates for research staff (BOE); ENAC. CDTI 2026 programme data (Neotec, Misiones) per cdti.es and zabala.es.
